#AskDrDurie: Why wasn’t panobinostat approved?
In this episode of #AskDrDurie, Dr. Brian G.M. Durie of the IMF answers a patient's question about why the recent FDA ODAC hearing rejected the use of new drug panobinostat for myeloma. He also discusses other HDAC inhibitors that are currently in development.
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.